French pharma giant navigating new therapies and market shifts
The NHS in England and Wales has approved teplizumab, the first drug that can delay onset of type 1 diabetes. The immunotherapy offers up to three extra years before symptoms require lifelong insulin, with rollout backed by NICE and a commercial deal with Sanofi.
The FDA has approved Lipfendra, Merck’s oral PCSK9 inhibitor, to lower LDL cholesterol in patients on statins. Trials show ~55-60% LDL reductions; the pill will be sold at about $315/month and must be taken on an empty stomach. Analysts see potential peak sales in the billions as injectable rivals face competition and access barriers.
Companies like Kalshi are expanding prediction markets to biotech trials, linking drug trial outcomes to tradable contracts. Bloomberg and The Guardian report Kalshi’s pilot, its safeguards, and regulatory concerns, as markets push for open data on trial probabilities amid regulatory decisions.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
President Trump has signed an executive order directing federal health officials to cut the federal recommended childhood vaccine list, to split the combined MMR vaccine into separate measles, mumps and rubella doses once single‑disease products are available, and to space routine immunisations across separate medical visits. Public health groups and drugmakers have said the changes lack scientific support and will increase missed vaccinations during a major U.S. measles outbreak.